Publication:
Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva (R)): a randomised, placebo-controlled trial

dc.contributor.authorDrobnic, Franchek
dc.contributor.authorRiera-Oliver, Joan
dc.contributor.authorAppendino, Giovanni
dc.contributor.authorTogni, Stefano
dc.contributor.authorFranceschi, Federico
dc.contributor.authorValle, Xavier
dc.contributor.authorPons, Antoni
dc.contributor.authorTur, Josep A
dc.date.accessioned2024-07-03T11:09:19Z
dc.date.available2024-07-03T11:09:19Z
dc.date.issued2014-06-18
dc.description.abstractBackground: Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural products, and is now commercially available as a lecithin delivery system (Meriva (R), Indena SpA, Milan) with improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise. Methods: This was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately active volunteers were randomised to curcumin given as the Phytosome (R) delivery system 1 g twice daily (200 mg curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported pain intensity was also recorded. Results: Subjects in the curcumin group reported less pain in the lower limb as compared with subjects in the placebo group, although significant differences were observed only for the right and left anterior thighs. Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No differences in markers of oxidative stress and muscle histology were observed. Conclusions: Curcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of curcumin.en
dc.description.sponsorshipProf. Martino Recchia (Medistat s.a.s.) is acknowledged for statistical analysis. Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD; this assistance was funded by Indena.es_ES
dc.format.page31es_ES
dc.format.volume11es_ES
dc.identifier.citationDrobnic F, Riera J, Appendino G, Togni S, Franceschi F, Valle X, et al. Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva (R)): a randomised, placebo-controlled trial. J Int Soc Sport Nutr. 2014 Jun 18;11:31.en
dc.identifier.doi10.1186/1550-2783-11-31
dc.identifier.e-issn1550-2783es_ES
dc.identifier.journalJournal of the International Society of Sports Nutritiones_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/11215
dc.identifier.pubmedID24982601es_ES
dc.identifier.scopus2-s2.0-84902300218
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19994
dc.identifier.wos338456600002
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://dx.doi.org/10.1186/1550-2783-11-31en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMeriva (R)
dc.subjectCurcumin
dc.subjectDOMS
dc.subjectSport nutrition
dc.titleReduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva (R)): a randomised, placebo-controlled trialen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files